KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

Abstract Background KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhi...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Journal of Translational Medicine
المؤلفون الرئيسيون: Pierre-Antoine Laurent, Marina Milic, Clément Quevrin, Lydia Meziani, Winchygn Liu, Daphné Morel, Nicolas Signolle, Céline Clémenson, Antonin Levy, Michele Mondini, Eric Deutsch
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2023-10-01
الموضوعات:
MRTX1257
Radiotherapy
KRAS inhibitors
Tumor
Radio-sensitizing
KRAS G12C
الوصول للمادة أونلاين:https://doi.org/10.1186/s12967-023-04619-0

الانترنت

https://doi.org/10.1186/s12967-023-04619-0

مواد مشابهة